• Talin1–Piezo1–YAP Axis in Atherosclerosis

  2026-10-10

  A 2026 study identifies Talin1 as a regulator linking Piezo1-mediated calcium influx to YAP-dependent endothelial inflammation in atherosclerosis models. Its combined human, mouse, and endothelial-cell evidence supports Talin1 as a mechanistic and potentially therapeutic target, while remaining insufficient to establish clinical efficacy or direct causality in patients.

• Masitinib (AB1010) Product Overview

  2026-10-09

  Masitinib (AB1010), SKU A2942, is listed as a phenylaminothiazole-type tyrosine kinase inhibitor targeting KIT and PDGFR pathways. The supplied information supports only product identity and conceptual research scope; no matched paper evidence is available for validating performance, mechanisms, or clinical outcomes.

• Epacadostat and IDO1 in Immunometabolism Research

  2026-10-08

  A source-grounded overview of Epacadostat (INCB024360), its proposed IDO1 mechanism, the relevance of standardized whole-blood immunometabolism assays, and the limits of translating biochemical or cytokine findings into immuno-oncology conclusions.

• Everolimus (RAD001): Reading Cancer Response

  2026-10-08

  Everolimus (RAD001) is more than an mTOR pathway inhibitor: its research value depends on distinguishing growth arrest from genuine cell killing. This evidence-centered guide connects mechanism, assay interpretation, and translational limits for cancer biology studies.

• 2X Taq PCR Master Mix: Evidence and Research Context

  2026-10-07

  A source-grounded overview of how a Taq-based PCR reagent may fit conceptual molecular studies of social ambrosia beetles, fungal disease transmission, and symbiotic defenses, with emphasis on published findings, evidence strength, and limitations.

• Imatinib Hydrochloride: Evidence and Research Context

  2026-10-07

  This overview places imatinib hydrochloride and STI571 hydrochloride in the context of kinase-driven cancer research, then compares supplier-reported target data with structural and biochemical findings from a preprint on dual-action p38α kinase inhibitors.

• Mitoxantrone Targets the ERα DBD–LBD Interface

  2026-10-06

  Wang et al. identify mitoxantrone as a ligand for an underexplored interface between the estrogen receptor alpha DNA-binding and ligand-binding domains. The study links this interaction to ERα relocalization, proteasomal degradation, suppression of therapy-resistant receptor mutants, and activity in breast cancer models, while distinguishing the mechanism from conventional hormone-pocket antagonism.

• JNJ-10198409 in PDGF Signaling Research

  2026-10-06

  JNJ-10198409 is described by APExBIO as a platelet-derived growth factor receptor inhibitor for nonclinical signaling research. This overview separates supplier-reported compound information from the primary findings of a 2025 Rice stripe virus study and explains why evidence from mammalian PDGF systems cannot be directly transferred to plant–vector virus biology.

• Capecitabine: Mechanism and Model Evidence

  2026-10-05

  Capecitabine is a fluoropyrimidine prodrug whose conversion to 5-fluorouracil supports tumor-selective pharmacology research. Evidence from patient-derived gastric assembloids shows that stromal context can change drug responsiveness, but this model study does not establish clinical efficacy for Capecitabine.

• Neem Extract, Catalase, and Cellular Aging

  2026-10-05

  Dang et al. connect neem leaf extract with lifespan extension and oxidative-stress resistance in yeast, then relate those findings to catalase-linked transcriptional responses and selected outcomes in human cells. The study’s cross-model design is mechanistically suggestive, but its findings remain preclinical and do not establish that neem extract prevents human aging.

• Carvedilol: Mechanisms, Evidence, and Research Context

  2026-10-04

  Carvedilol is a nonselective β-adrenergic receptor antagonist with additional α1-adrenergic activity. This overview compares its established pharmacological context with emerging findings on hematopoietic regeneration, while distinguishing primary evidence from supplier-reported antioxidant, vascular, and cardioprotective claims.

• Novobiocin Sodium: Evidence Beyond Antibacterial Action

  2026-10-03

  Novobiocin Sodium is an aminocoumarin antibiotic whose research value extends from DNA gyrase biology to host–pathogen selectivity questions. This evidence-focused review examines the 2024 Toxoplasma gondii study, clarifies what its findings do—and do not—demonstrate, and identifies responsible directions for future research.

• Pomalidomide (CC-4047) for Reliable Cell Assays

  2026-10-02

  This scenario-driven guide explains how Pomalidomide (CC-4047), SKU A4212, can support reproducible viability, cytokine, and erythroid progenitor assays. It connects concentration selection, solvent handling, multiple myeloma model heterogeneity, and vendor evaluation to documented product and literature evidence.

• gamma-Glu-Cys (γ-Glu-Cys) Workflow Guide

  2026-10-01

  This practical guide explains how to use gamma-Glu-Cys (γ-Glu-Cys) as a defined L-glutathione biosynthesis intermediate in glutathione synthetase enzyme assay development and related pathway studies. It covers identity checks, solvent selection, fresh-solution handling, controls, and limitations; the material is for scientific research only and is not validated for diagnostic, therapeutic, or clinical use.

• RapaLink-1 Workflows for mTORC1 Research

  2026-10-01

  RapaLink-1 is a third-generation mTOR inhibitor suited to resistance-focused oncology assays, glioma phenotyping, and carefully controlled studies of mTOR-dependent dormancy. This practical guide connects its bivalent mechanism with dose selection, pathway readouts, recovery experiments, and troubleshooting for reproducible research.

8445 records 1/563 page Next 12345 下5页 Last page